`
`Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With
`Two Doses of Glatiramer Acetate (GA) (FORTE)
`
`BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a
`Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
`
`Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (DEFINE)
`
`Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One (CARE-MS
`I) (CAMMS 323)
`
`Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two (CARE-MS
`II) (CAMMS 324)
`
`A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
`
`Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With
`Optional Extension Phase (TRANSFORMS)
`
`Treatment Interruption of Natalizumab (RESTORE)
`
`FTY720 in Patients With Primary Progressive Multiple Sclerosis (INFORMS)
`
`BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (ENDORSE)
`
`A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the
`Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered
`Three Times a Week Compared to Placebo (GALA)
`
`STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod
`(START)
`
`Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab
`in Adult Participants With Relapsing Multiple Sclerosis (MS) (REFINE)
`
`A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in
`Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)
`
`A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With
`Gilenya® (PASSOS)
`
`The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting
`Multiple Sclerosis (RRMS) (CONCERTO)
`
`
`
`Page 1 of 2
`
`YEDA EXHIBIT NO. 2132
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`
`
`
`
`A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the
`Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or
`1.5mg/Day (Experimental Drug) as Compared to Placebo
`
`Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated
`With Interferon-beta (TERACLES)
`
`Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
`(TOPAZ)
`
`Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With
`Relapsing-remitting Multiple Sclerosis (Biobank)
`
`(CBAF312A2201) - A phase II, double-blind, randomized, multi-center, adaptive dose-ranging,
`placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI
`lesion parameters and determining the dose response curve of BAF312 given orally once daily in
`patients with relapsing-remitting multiple sclerosis
`
`Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients
`
`JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) (JEMS)
`
`A Phase I, sequential group, randomized, double-blind, placebo-controlled study to assess the
`tolerability and safety of escalating doses of oral laquinimod administered daily in subjects with
`relapsing remitting multiple sclerosis (RRMS)
`
`Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With
`Relapsing-remitting Multiple Sclerosis
`
`A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
`
`Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in
`Participants With Relapsing-Remitting Multiple Sclerosis ((DECIDE))
`
`A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With
`Relapsing Multiple Sclerosis
`
`A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
`
`Dose-finding Study of MT-1303
`
`Phase 3 Study of RPC1063 in Relapsing MS
`
`
`
`
`
`
`2
`
`Page 2 of 2
`
`YEDA EXHIBIT NO. 2132
`MYLAN PHARM. v YEDA
`IPR2015-00644
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
